Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours

References

• Waxman S. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6: 3–10.
   PubMed Web of Science ®Google Scholar
• Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med 1993; 86: 287–9.
   PubMed Web of Science ®Google Scholar
• Forkner C, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3–5.
   Google Scholar
• Tarnowski GS, Schmid FA, Cappuccino JG, Stock CC. Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals. Cancer Res 1966; 26: 181–206.
   PubMed Web of Science ®Google Scholar
• Knock FE, Galt RM, Oester YT, Sylvester R. The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer. Surg Gynecol Obstet 1971; 133: 458–66.
   PubMedGoogle Scholar
• Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen Si, Chen Z, Wang ZY. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leu-kemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–60.
   Google Scholar
• Tamm I, Paternostro G, Zapata JM. Treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1999; 340: 1043; discussion 1044–5.
   Google Scholar
• Wang Z. To develop clinical and experimental studies for arsenic to treat leukemia. Chin J Hernatol 1996; 2: 56.
   Google Scholar
• Zhang P, Wang, SY, Hu LH, Shi, FD, Qiu FQ, Hong GJ. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hernatol 1996; 2: 58.
   Google Scholar
• Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti Li, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–8.
   Google Scholar
• Murgo Ai. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001; 6 (Suppl 2): 22–8.
   Google Scholar
• Gallagher RE. Arsenicnew life for an old potion. N Engl J Med 1998; 339: 1389–91.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhu J, Shi XG, Ni JH, Zhong Hi, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen Si, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052–61.
   PubMed Web of Science ®Google Scholar
• Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978–83.
   Google Scholar
• Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/ RAR alpha protein in acute promyelocytic leukemia cells. J Nall Cancer Inst 1998; 90: 124–33.
   Google Scholar
• Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen Si, Zhang TD, Waxman S, Chen Z, Chen GQ. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Nall Cancer Inst 1999; 91: 772–8.
   PubMed Web of Science ®Google Scholar
• Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893–903.
   PubMed Web of Science ®Google Scholar
• Lew YS, Brown SL, Griffin RJ, Song CW, Kim JR. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033–7.
   Google Scholar
• Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, Park H, Song CW. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000; 2: 555–60.
   PubMed Web of Science ®Google Scholar
• Lew YS, Kolozsvary A, Brown SL, Kim JR. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 2002; 62: 4202–5.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12–25.
   PubMed Web of Science ®Google Scholar
• Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y. Arsenic trioxide (As203)-induced apoptosis and differentia-tion in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-produ-cing transgenic SCID mice. Leukemia 2000; 14: 431–8.
   Google Scholar
• Maeda H, Hon S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As203) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432–40.
   Google Scholar
• Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, Pahlman S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000; 277: 179–85.
   Google Scholar
• van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–25.
   PubMed Web of Science ®Google Scholar
• Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287–95.
   Google Scholar
• Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 1996; 14: 131–7.
   PubMedGoogle Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829–34.
   PubMed Web of Science ®Google Scholar
• Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54: 1497–502.
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apop-tosis protein survivin regulates vascular injury. Nat Med 2002; 8: 987–94.
   Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1518–23.
   PubMed Web of Science ®Google Scholar
• Kanamori S, Nishimura Y, Okuno Y, Horii N, Saga T, Hiraoka M. Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Int J Hyperthermia 1999; 15: 267–78.
   PubMed Web of Science ®Google Scholar
• Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol 2001; 12: 1135–48.
   PubMed Web of Science ®Google Scholar
• Kruskal JB, Oliver B, Huertas JC, Goldberg SN. Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tissue in mice. J Vasc Interv Radiol 2001; 12: 1193–201.
   PubMed Web of Science ®Google Scholar
• Witkamp Ai, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27: 365–74.
   PubMed Web of Science ®Google Scholar
• Sapirstein L. Regional blood flow by fractional distribution of indicators. Am J Physiol 1958; 193: 161–8.
   PubMed Web of Science ®Google Scholar
• Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776–80.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileuke-mic effect via inhibition of angiogenesis. Blood 2000; 96: 1525–30.
   Google Scholar
• Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984; 44: 4721s–30s.
   Google Scholar
• Vaupel P. Vascularization, blood flow, oxygenation, tissue pH, and bioenergetic status of human breast cancer. Adv Exp Med Biol 1997; 411: 243–54.
   PubMed Web of Science ®Google Scholar
• Vaupel P. Physiological properties of malignant tumours. NMR Biomed 1992; 5: 220–5.
   PubMed Web of Science ®Google Scholar
• Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111–37.
   PubMedGoogle Scholar
• Kallinowski F, Schlenger KR, Kloes M, Stohrer M, Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micro-milieu of human tumor xenografts in vivo. Int J Cancer 1989; 44: 266–72.
   Google Scholar
• Lefor AT, Foster 3rd, CE, Sartor W, Engbrecht B, Fabian DF, Silverman D. Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte adhesion to endothelial cells. Surgery 1994; 116: 214–20; discussion 220-11.
   Google Scholar
• Gnant MF, Turner EM, Alexander HR Jr. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine 2000; 12: 339–47.
   Google Scholar
• Chang WC, Chen SH, Wu HL, Shi GY, Murota S, Morita I. Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Toxicology 1991; 69: 101–10.
   PubMed Web of Science ®Google Scholar
• Rocksen D, Lilliehook B, Larsson R, Johansson T, Bucht A. Differential anti-inflamma-tory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Imrnunol 2000; 122: 249–56.
   Google Scholar
• Bernstam L, Nriagu J. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 2000; 3: 293–322.
   PubMed Web of Science ®Google Scholar
• Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 1996; 21: 783–90.
   PubMed Web of Science ®Google Scholar
• Jones EL, Douple EB. The effect of in vivo GSH depletion on thermosensitivity, radio-sensitivity and thermal radiosensitization. Int J Hypertherrnia 1990; 6: 951–5.
   PubMed Web of Science ®Google Scholar
• Seibert H, Morchel S, Gulden M. Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicol In Vitro 2002; 16: 289–97.
   Google Scholar
• Griffin RJ, Ogawa A, Song CW. A novel drug to reduce tumor perfusion: antitumor effect alone and with hyperthermia. Radiat Res 2000; 154: 202–7.
   Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hypertherrnia 2001; 17: 508–19.
   Google Scholar
• Kozin SV, Hasegawa T, Ha-Kawa SK, Akagi K, Tanaka Y. Hydralazine at thermora-diotherapy: tumor size and blood flow effects. Int J Radiat Oncol Biol Phys 1994; 29: 505–10.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408–16.
   Google Scholar